Donato Ciaccia, MD
Gastroenterology · Indianapolis, INNPI 1265491385
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (58.5%), food and beverage and education — rather than concentrated in one kind of arrangement. 13 manufacturers reported payments, led by Boston Scientific at 45.2% of the total. Reporting peaked in 2019 at $1,850 and has fallen 69.7% since, to $562 in 2025.
Across 92 payments — averaging $61.10 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boston Scientific$3K
- Olympus Corporation Of The Americas$2K
- AbbVie$441
- Steris Corporation$273
- Johnson & Johnson$99
- Nestle Healthcare Nutrition Inc.$96
- plus $211 from 7 others
What the payments were for
- Travel & lodging$3,28959%
- Food & beverage$2,23340%
- Education$992%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boston Scientific | 22 | $2,540 |
| Olympus Corporation Of The Americas | 25 | $1,961 |
| AbbVie(2 entities) | 27 | $441 |
| Steris Corporation | 2 | $273 |
| Johnson & Johnson | 1 | $99 |
| Nestle Healthcare Nutrition Inc. | 2 | $96 |
| Bristol Myers Squibb | 4 | $58 |
| Aimmune Therapeutics, Inc. | 2 | $49 |
| Regeneron Healthcare Solutions, Inc. | 1 | $35 |
| Gilead | 2 | $31 |
| Olympus America Inc. | 1 | $19 |
| Ironwood Pharmaceuticals, Inc | 1 | $12 |
| Micro-tech Endoscopy USA, Inc. | 2 | $7 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$5,621 in reported general payments places this provider in the 70th percentile of 323 gastroenterology providers in Indiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Sucralfate | 53 | $7,757 |
| Mesalamine | 13 | $3,591 |
| Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl | 191 | $3,050 |
| Azathioprine | 33 | $2,940 |
| Dexlansoprazole DrDexlansoprazole | 12 | $2,900 |
| Pantoprazole Sodium | 113 | $2,018 |
| Omeprazole | 60 | $1,402 |
| Colestipol Hcl | 11 | $1,143 |
| Famotidine | 59 | $910 |
| Dicyclomine Hcl | 12 | $432 |
| Ondansetron OdtOndansetron | 97 | $229 |
| Ondansetron Hcl | 48 | $78 |
Paid to pharmacies, not to this prescriber.
Other gastroenterology in Indianapolis
- Douglas RexIndianapolis$557K
- Ajay JainIndianapolis$432K
- Monika FischerIndianapolis$258K
- Naga ChalasaniIndianapolis$255K
- Thomas ImperialeIndianapolis$188K
- Mark GromskiIndianapolis$154K
- David PoundIndianapolis$137K
- Glen LehmanIndianapolis$87K
- Samer GawriehIndianapolis$78K
- Stuart ShermanIndianapolis$52K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.